Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]

17304 reported adverse events

Drugs of this class: IVACAFTOR LUMACAFTOR AND IVACAFTOR VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR

These side effects are most commonly reported by patients taking drugs of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] class:

# Side effect Count
0 HOSPITALISATION 2340
1 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 2107
2 DYSPNOEA 740
3 COUGH 640
4 INFECTION 640
5 CYSTIC FIBROSIS 565
6 PNEUMONIA 558
7 PULMONARY FUNCTION TEST DECREASED 543
8 MALAISE 487
9 CHEST DISCOMFORT 437
See all common reactions for Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]

Drugs of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SWEAT TEST ABNORMAL 28 0.4118
1 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 2107 0.3867
2 CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION 237 0.2654
3 CYSTIC FIBROSIS LUNG 27 0.2109
4 DISTAL INTESTINAL OBSTRUCTION SYNDROME 51 0.1513
5 PULMONARY FUNCTION TEST DECREASED 543 0.1239
6 CYSTIC FIBROSIS 565 0.1019
7 FORCED EXPIRATORY VOLUME DECREASED 173 0.0610
8 PSEUDOMONAS TEST POSITIVE 33 0.0403
9 SPUTUM INCREASED 86 0.0397
See all enriched reactions for Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]